The market’s been twitching lately. A nervous tick in a heavyweight. Most folks get spooked. They run for cover. Smart money? It looks for the angles. The ones where the risk is worth a good, hard look. I’ve been doing just that, and I’ve found two names that seem to have more than just hope going for them. They’ve got something resembling a plan. And in this town, that’s a rare commodity.
I’m talking about Eli Lilly (LLY 1.01%) and Veeva Systems (VEEV +2.75%). They aren’t glamorous. They won’t make headlines with every breath. But they’re building something. Something that might just stick around when the dust settles. Let’s take a look under the hood.
1. Eli Lilly
Lilly. The name used to conjure images of little old ladies and sugar pills. Not anymore. This isn’t your grandfather’s pharmaceutical company. They’re moving fast, and frankly, it’s unsettling. They’ve been growing like a weed in a fertilizer factory. The numbers aren’t just good; they’re bordering on arrogant.
They’ve cornered the weight loss market with tirzepatide. A drug that’s become more popular than common sense. Last year it was the best-selling drug in the world. That’s not luck. That’s a carefully crafted machine. They’re not stopping there. They’ve got an oral version coming – forglipron – and a pipeline full of possibilities. Diabetes, obesity, immunology, oncology… they’re throwing darts at the board and hitting bullseyes.
They’re also playing with AI, which, in this town, usually means throwing money at a problem and hoping it disappears. But Lilly seems to be doing it right. They’re using it to accelerate drug development, to market their products. It’s a gamble, sure. But a calculated one. This isn’t a company resting on its laurels. It’s a predator, and it’s hungry. And in this business, that’s a good sign.
2. Veeva Systems
Veeva. The name sounds like a new strain of virus. But it’s cloud solutions for life science companies. They cater to the big boys – Lilly included. They don’t just sell software; they sell peace of mind. In an industry drowning in regulations and red tape, that’s worth a premium.
They’ve built a fortress. Over 1,500 customers. Consistent revenue. Consistent earnings. The competition is getting fiercer, sure. But Veeva has a moat. High switching costs. Once you’re in their ecosystem, it’s hard to get out. It’s like trying to escape a quicksand. They’re not flashy. They’re reliable. And in this business, reliability is a rare and valuable commodity.
They’re estimating a $20 billion addressable market. Currently, they’re at $3.1 billion in revenue. They’re aiming to double that revenue by 2030. That’s a bold claim. But it’s not unreasonable. The stock’s been beaten down lately. Trading near its 52-week low. That’s an opportunity. A chance to buy a solid company at a reasonable price. In this town, those are getting harder to find.
I’m not saying these stocks are a sure thing. Nothing is. But they’ve got the fundamentals. The growth potential. And, most importantly, a plan. In a world full of noise and uncertainty, that’s enough for me to take a closer look. And maybe, just maybe, make a little money.
Read More
- Gold Rate Forecast
- Top 15 Insanely Popular Android Games
- Did Alan Cumming Reveal Comic-Accurate Costume for AVENGERS: DOOMSDAY?
- 4 Reasons to Buy Interactive Brokers Stock Like There’s No Tomorrow
- Silver Rate Forecast
- EUR UAH PREDICTION
- DOT PREDICTION. DOT cryptocurrency
- ELESTRALS AWAKENED Blends Mythology and POKÉMON (Exclusive Look)
- New ‘Donkey Kong’ Movie Reportedly in the Works with Possible Release Date
- Core Scientific’s Merger Meltdown: A Gogolian Tale
2026-03-04 03:22